¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º m|O7@N  
RhG9Xw9  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ %#rH~E  
s!q6OVJ-  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) Y9TaU]7]  
1 )aB']K%  
1. ICAM-1 Tsez&R$k  
Ojx1IL  
2. interleukin 12(IL-12) qbjLTE=  
Y5~_y?BX  
3. tumor infiltrating lymphocyte "lo:"y(u  
{XMF26C#  
4. TCR/CD3 complex -d+q+l>0  
qV$\.T>x  
5. hematopoietin receptor family \: H&.VQ"  
ic:_v?k  
6. individual idiotype(IdI) .17WF\1HC.  
5-Vdq  
7. integrin  _2VL%  
%aU4d e^  
8. colony-stimulatory factor (CSF) ( w(GJ/g  
/wB<1b"  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© )W!8,e+%  
'~{^c}  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? gaaW:**y  
 9x/HQ(1  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ LlP_`fA  
 vgSs]g  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠMP\$_;&xB  
<N11$t&_  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ %  (R10G  
wSHE~Xx  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) Ep/4o< N(  
p#W[he  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ m5lMh14E  
c Q~}qE>I  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) U`_(Lq%5W  
n*G[ZW*Uc  
3. immunoglobulin superfamily (IgSF) uBI?nv,  
>VnkgY  
4. selectin %pmowo~{  
)=TD}Xb  
5. anti-idiotypic antibody (¦ÁId) qepsR/0M  
 K*Y.mM)  
6. major histocompatibility complex(MHC) `T2RaWR4=  
8`Fo ^c=j  
7. immunotolerance 6>ZUx}vYj  
xoI;s}*E  
8. biological reponse modifier(BRM) kxt@t#  
RWtD81(oC'  
9. immune reponse gene (Ir gene) O1IR+"0  
I=X-e#HM?  
10. reshaped antibody (or reconstituted antibody) #y13(u,dN  
MkZm =Sf  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© :U!knb"/>  
v'0A$`w`  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ &3l g\&"  
o %sBU  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? [mph iH/  
=jIB5".  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ ^T`)ltI]V  
0FmYM@Wc  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? U 8L%=/N>B  
braHWC'VYg  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ VqqI%[!Aw  
:xISS  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? )*@n G$i99  
asqbLtQ  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 8enlF\I8g  
`%}SK~<R  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ ! iuD mL  
:U_k*9z}=  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? vI3L <[W  
9x@( K|  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 6L[Yn?;  
^=:e9i3u  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ("-Co,4ey  
BM5+;h !  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ,:POo^!/fT  
R:c$f(aKv%  
ÃâÒßѧ ("07t/||  
\6o%gpUkD  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© B1)gudP`  
-xs @rV`  
1. CD8 0Oy.&C T  
-X+G_rY  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) R-8>,  
iAD'MB  
3. immunoglobulin fold(Ig fold) u#(VR]u\7  
M)4-eo  
4. cadherin (Ca-dependent cell adhesion moleculers) -]yM<dP  
O@.C.5Ep  
5. idiotype-anti-idiotypic antibody immune network theory ILi{5L  
E4;vC ?K{  
6. HLA class II antigen cV]c/*z A  
OpFe=1Q  
7. complementarity-determining region (CDR) @BQJKPF *  
"#zSk=52z  
8. perforin(or pore-forming protein ,PFP) KnL-qc  
|v,%!p s  
9. high affinity IL-2 receptor {A!1s;  
9!'qLO  
10. artificial active immunization SURbH;[   
Y9V%eFY5E  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© TCShS}q;%  
2gP^+.  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠk;EG28   
_:dt8+T#  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 NsbC0 xLd  
DX3xWdnr  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ sKE7U>mz|  
Eo h4#fZ\N  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ `)i'1E[9  
NT(gXEZ  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ YoC{ t&rY  
SNLZU%jan  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? jVW .=FK  
5a8[0&hA 2  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ k[_)5@2  
KImBQ2^Tu  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ n,,hE_  
4?eO1= a  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ tr[(,kX  
aL)}S%5o?  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ FCr^D$_w  
&- 5`Oln  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© G 51l_  
jRn5)u  
1. immunoglobulin gene rearrangement N*^iOm]Y  
<^+x}KV I  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) T O]wD^`  
1\t#*N  
3. flow cytometry(FCM) NA :_yA"  
2`Dqu"TWh  
4. carrier effect {fd/:B 7T  
 L- '{   
5. positive selection of T lymphocytes in thymus &EUI  
LMGo8%2I  
6. mouse TH1(Th1) and TH2(Th2) subsets SlaHhq3  
og?>Q i Tr  
7. perforin (pore-forming protein ,PFP) _N @ h  
x$SxGc~4gb  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) 1WP(=7$.  
^ ,cwm:B@  
9. SH-2(src-homology region 2) uY_vX\;67z  
Z[Z3x6 6  
10. Ab2¦Â (internal image) 5 LX'fL7zU  
78MQoG<  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© S - N [  
u3k{s  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? hI#1Ybl  
NZQl#ZJH:  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? [6u8EP0xM  
x & ZW f?  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠJ$>9UC k7B  
Chs#}=gzi  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ tb1w 6jaU  
= }!4%.$  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠX+%5q =N  
1w$X;q"  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) n7p,{KSQ  
"q]r{0  
ÃâÒßѧרҵ£º w|G4c^KH  
8h '~*  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ .QLjaEja  
-L6V)aK&  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? mzbMX <  
]w5j?h"b  
´«È¾²¡Ñ§×¨Òµ£º B.Y8O^rx  
}1BpIqee  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ q_b,3Tp  
B(ZK\]  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ lBZhg~{  
EHlkt,h*  
Ïû»¯×¨Òµ£º yk0#byW`  
;a9`z+ K  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£  )k6O  
egn9O  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 5-B %08T  
;0JK>c ]#  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ kNC]q,ljt5  
{Q/_I@m].  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© P~9y}7Q\0  
PlC8&$   
1. Fas(CD95)/FasL }~+_|  
M|9=B<6`7  
2. common chain of cytokine receptor q6AL}9]9  
K0-AP $  
3 . TCR/CD3 complex i7|sVz=  
3x3 =ke!  
4. negaive selection of thymocytes "3e1 7dsY  
oeF0t'%  
5. artificial active immune 9`|~- b  
$e/[!3CASP  
6. anti-idiotypic `\M}~  
K;P<c,9X/  
7. IgSF _2wH4^Vb  
yd~}CF  
8. Integrin NKRI|'Y,  
vfpK|=[7o  
9. chemokine x>eV$UJ  
3.@ I\p}  
10. B7/CD28 K/IG6s;Xj  
"Wn8}T*  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© ]>H'CM4JR  
)Nkf'&  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£  i=aK ?^+  
~X<Ie9m1x  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ Uk<2XGj  
y*7<tj.`b0  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ hVf;{p &  
0;SRmj@W  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ &KP JB"0L  
o@ W:PmKW  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ AH'4k(-  
g#s hd~e  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ ql2O%B.6?  
la{Iqm{i  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© G * '1[Bu  
9ELRn @5.  
1. B7/CD28 m'YYkq(5%Z  
X(dHh O  
2. Th1 subset {~{</ g/  
t;L7H E@Y  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© =L9;8THY  
ObEp0-^?  
4. antibody affinity maturation }/g1s71  
) ={ H  
5. AP-1 (8jQdbZU  
1rGi"kdf  
6. single chain variable fragment£¨ScFv£© [&K"OQ^\2h  
(U^f0wJg  
7. NK cell receptor H&h"!+t(#  
R~H+.Vh  
8. Zinkernagel-Doherty phenomenon -$tf`   
&LDA=B  
9. Ig fold 'q, L*  
9KDm<Q-mf  
10. CD40/CD40L 0S$6j-"  
`z~L0h  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© 2R>!Wj'G+o  
f&88N<)  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ vCsJnKqK  
-PLh|  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ >@?`n}r|  
s]Qo'q2  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ | rwx; +  
 #[yZP9  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ NNn sq@?6  
}^]TUe@a  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ ;I!Vba  
4 'GosQ85  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ WIYWql>*  
Twq,6X-  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ `C>De4nT@  
zp:EssO=Q  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© UB3hC`N\  
G}#p4 \/  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ]Ia}H+&  
(=t41-l  
1.Co-stimulators (or co-stimulating molecules) OXD*ZKi8  
{q.|UCg[ L  
2.NK-kB cNiNLwc  
\.Z /  
3.Immunoglobulin superfamily M{Hy=:K+  
Bnh*;J0  
4.antigen-presenting cell (APC) h4N&Yb fo  
^\7GFpc  
5.death domain 2|$G<f  
CM4#Nn=i~  
6.CCR and CXCR g ![?P"i^t  
O[15x H,  
7.Lectin (or mitogen) &{ZTtK&JF  
L^e%oQ>s  
8.Clusters of differentiation, CD) UqNUP+K  
:aWC6"ik-W  
9.B7 family v?s%qb=T  
wPl9%  
10.Cytotoxic T lymphocyte, CTL) B~47mw&b  
Y%Tm `$^V  
11.IL-15 and IL-15 receptor (IL-15R) 8]&\FA8  
Hgbrlh  
12.MHC restriction ~qkn1N%'  
k FCdGl  
13.Affinity-chromatography +k\cmDc b  
T[%@B"  
14.Cyctosprin A, CsA t (Gg 1  
>j)y7DSE  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) nTCwLnX(O  
/A93mY[  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© lK3{~ \J-  
M?QX'fia  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ZiC~8p_f  
0X4I-xx#  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ u1ahAk7  
a]@BS6  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£  _:HQ4s@  
rkn'1M&u  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© qqSFy>`P  
,tak{["  
ÃâÒßѧרҵ£º  I}u&iV`  
V z-]H]MW,  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ }s:~E2?In  
IC +!XZqS  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ bVOJp% *s  
c{[lT2yxU  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ 6rMNp"!  
 }A&I@2d  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) =)nJ'}x  
.q|k459oi  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) :H>0 /^Mg0  
2*a5pFkb  
1. ADCC(antibody dependent cell-mediated cytotoxicity) nhRpb9f`1@  
cFr `9A\-n  
2. »·æß¾úËØ(cyclosporin) pyp0SGCM:  
k(M(]y_  
3. KIR(killer cell inhibitory receptor) {!^0j{T  
7 yUX]95y8  
4. HLDA(human leucocyte differentiation antigen) 5A+r^xN  
Dq+S'x~>  
5. Interleukin 18(IL-18) RaOLy \  
C4)m4r%  
6. ÕûºÏËØ(integrin) !vq|*8  
.yB{+  
7. Fas/FasL  GK1oS  
}#6~/ W  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) ATjE8!gO!  
R#ZO<g%'  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) X'j9l4Ph7  
ANTWWs}  
10. Th1/Th2 eV j7%9  
k|^`0~E  
11. »ùÒòÒßÃç(DNAÒßÃç) O bc>f|l]  
]I\9S{?  
12. chemokines and chemokine receptor ]q/USVj{  
&]pY~zVc  
13. ÃâÒßÄÍÊÜ c$x >6&&L  
>4J(\'}m|  
14. ¹²´Ì¼¤·Ö×Ó ~SS3gLv  
SGu`vN]  
15. ËÀÍö½á¹¹Óò(death domain) lN x7$z`  
<`WcI`IA b  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) e xkPu-[W  
PJ\k |  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? 7&u$^c S(  
Nh\o39=  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠJ?Oeuk~[D  
D 9UM8Hxi  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î ,&L} ^Up  
$W%-Mm  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ wo;OkJKF  
d4p6.3  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå _fSBb<  
!(gSXe)*  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ e^;%w#tEqI  
?!O4ia3nFk  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) HiBI0)N}  
Vcnc=ct  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ RhC|x,E  
8H|ac[hXK2  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ nLCaik_,m  
Ks<+@.DLTu  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»